logo
  

Moderna Says Bivalent COVID-19 Booster Shows Superior Antibody Response Against Omicron

Biotechnology company Moderna Inc.(MRNA) said Wednesday that its omicron-containing bivalent booster candidate mRNA-1273.214, which contained mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern, demonstrated superior antibody response against omicron.

According to the company, mRNA-1273.214 met all primary endpoints in the phase 2/3 trial including neutralizing antibody response against Omicron when compared to a 50 micrograms booster dose of mRNA-1273 in baseline seronegative participants. The study results showed mRNA-1273.214 exhibited an eight-fold boost in neutralizing geometric mean titers against omicron among baseline seronegative participants.

The mRNA-1273.214 50 micrograms booster dose was well-tolerated in the 437 study participants. The safety and reactogenicity profile of the mRNA-1273.214 50 micrograms booster dose was similar to that of mRNA-1273 50 micrograms dose when these vaccines were administered as a second booster dose, the company said in a statement.

Results from the company's Beta-containing bivalent booster candidate, mRNA-1273.211, announced in April 2022, demonstrated superiority against Beta, Delta and Omicron variants of concern one month after administration, with continued superiority that was durable against Beta and Omicron variants of concern six months after administration.

Moderna anticipates that antibody titers induced by mRNA-1273.214 will be more durable over time against Omicron as compared to mRNA-1273. Moderna will report data from Day 91 after vaccination later in the summer.

Moderna plans to submit the interim analysis and data to regulators for review in the coming weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration said it now intends to review only a small subset of new emergency use authorization or EUA requests for diagnostic tests. As per an updated COVID-19 test policy with a view to ensure continued access to tests, the regulator further urged developers of all test types seeking marketing authorization to pursue traditional premarket review for most test types. Netflix, Inc. said it is adding a new feature to offer a more personalized mobile games experience on the platform. In a statement, Sophia Yang, Product Manager, Mobile Games, said the company is rolling out the ability to create game handles, with which members will be able to create a unique public username. This can be used across all Netflix games. General Motors Co. has delayed its plan to require employees to return to office many days a week until next year, reports said citing an internal memo signed by CEO Mary Barra. Last week, the company had announced that corporate workers would be required to return to respective offices at least three days a week, beginning later this year, as the COVID-19 pandemic eases.
Follow RTT